CYP20A1

Across TCGA pan-cancer cohorts, CYP20A1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CYP20A1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CYP20A1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CYP20A1 expression acts as an unfavorable survival marker, although some lineages such as GBM and CCRCC show a favorable association.

PDAC, GBM, and CCRCC are the cancer types where CYP20A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.411	0.622	.008	13	view →
GBM	DFS	Median	All	0.495	0.254	.007	9	view →
CCRCC	DFS	Median	III,IV	1.000	0.821	.020	7	view →
LUAD	OS	Tertile	II,III,IV	0.770	1.000	.022	6	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CYP20A1–PDAC (OS)

Open the PDAC breakdown →